Publication | Closed Access

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

OncologyMedicinePathologyColorectal CancerMetastatic Colorectal CancerMolecular OncologyCancer TreatmentPharmacologyRadiation OncologyCancer Research